For example, when stage T3 tumours were compared with stage T2 tumours, the HR+/HER2− and HR−/HER2− subtypes showed clear differences in survival, while HR+/HER2+ and HR−/HER2+ subtypes showed minimal differences. This evidence concerns the gene HR and neoplasm.